上海挚盟医药科技

Zhimeng Biopharma is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, specializing in the development of innovative therapies for chronic hepatitis B (CHB) and central nervous system (CNS) diseases. The company's lead candidate, ZM-H1505R, is a novel HBV capsid assembly modulator currently in Phase 2 clinical trials, designed to disrupt the viral life cycle as part of a functional cure strategy. Beyond virology, Zhimeng is advancing a pipeline of small molecule modulators targeting KCNQ2/3 potassium channels for the treatment of epilepsy and other neurological disorders. With a focus on high-unmet-need areas, the company leverages its expertise in medicinal chemistry to develop highly potent and selective drug candidates.